Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

July 1, 2009

View Archives Issues

  • Mean streets: Out of prison, out of HIV med compliance

    [Editor's note: A new study finds a large care gap that imperils the public health response to HIV prevention and treatment. When prisoners are released into the community, they often do not seek care or access their HIV medications. In this issue of AIDS Alert, we examine the implications of this problem and how the study reached its conclusions. Also, in the August, 2009, issue of AIDS Alert, we'll have a story about a New York prison re-entry program that serves as a vehicle for HIV prevention, as well as a way to reduce prison recidivism.]
  • Most HIV-infected inmates are eligible for ART

    A new study with surprising results about the low percentage of HIV-infected inmates accessing antiretroviral therapy (ART) post-release could be seen as a model for following this population.
  • Clinician's Corner: Researchers weigh continuing benefits of having HIV specialists

    HIV care in industrialized nations might best be served by a coordinated system of care that includes a general practitioner working with an HIV clinic, research suggests.
  • ART prescribing patterns evolve over past decade

    Research has found that combination antiretroviral therapies and studies showing superior benefits of some drugs over others have led to wide acceptance in recent years for two initial therapy regimens.
  • 2nd generation female condom OK'd by FDA

    Female-controlled HIV prevention options are set to expand with the Food and Drug Administration (FDA) March 2009 approval of the second generation of the female condom manufactured by the Female Health Co.
  • Abstract & Commentary: Guidelines: Opportunistic infections and HIV patients

    hese guidelines were last updated for adults in 2002 and for adolescents in 2004. The document (available in pdf format through the link above) is a 209-page file containing 1,391 references which update current recommendations for the prophylaxis and treatment of HIV-related OIs. As with most guidelines published in recent years by professional societies, a well-qualified expert panel has thoroughly reviewed both new and old data and has developed a relatively comprehensive document which will be of use to physicians who treat complicated HIV patients.
  • FDA Notifications

    On May 29, 2009, the Food and Drug Administration (FDA) granted tentative approval for generic lamivudine/zidovudine tablets 150 mg/300 mg indicated for treatment for Human Immunodeficiency Virus (HIV) in patients with or without Acquired Immunodeficiency Syndrome (AIDS).
  • Many young, black MSM unaware of HIV positivity

    The alarming number of young HIV-infected men who have sex with (MSM) who do not know they are infected is driving transmission in this disproportionately emerging population in the AIDS epidemic, the Centers for Disease Control and Prevention reports.